This company has been marked as potentially delisted and may not be actively trading. Third Harmonic Bio (THRD) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrendsBuy This Stock THRD vs. ORIC, IOVA, GERN, UPB, TRVI, IMNM, URGN, QURE, NEO, and PHATShould you be buying Third Harmonic Bio stock or one of its competitors? The main competitors of Third Harmonic Bio include Oric Pharmaceuticals (ORIC), Iovance Biotherapeutics (IOVA), Geron (GERN), Upstream Bio (UPB), Trevi Therapeutics (TRVI), Immunome (IMNM), Urogen Pharma (URGN), uniQure (QURE), NeoGenomics (NEO), and Phathom Pharmaceuticals (PHAT). These companies are all part of the "med - biomed/gene" industry. Third Harmonic Bio vs. Its Competitors Oric Pharmaceuticals Iovance Biotherapeutics Geron Upstream Bio Trevi Therapeutics Immunome Urogen Pharma uniQure NeoGenomics Phathom Pharmaceuticals Oric Pharmaceuticals (NASDAQ:ORIC) and Third Harmonic Bio (NASDAQ:THRD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment. Is ORIC or THRD more profitable? Third Harmonic Bio's return on equity of -19.27% beat Oric Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Oric PharmaceuticalsN/A -51.75% -47.09% Third Harmonic Bio N/A -19.27%-18.67% Which has more volatility & risk, ORIC or THRD? Oric Pharmaceuticals has a beta of 1.69, meaning that its share price is 69% more volatile than the S&P 500. Comparatively, Third Harmonic Bio has a beta of 2.12, meaning that its share price is 112% more volatile than the S&P 500. Do insiders and institutionals have more ownership in ORIC or THRD? 95.1% of Oric Pharmaceuticals shares are owned by institutional investors. Comparatively, 94.0% of Third Harmonic Bio shares are owned by institutional investors. 6.8% of Oric Pharmaceuticals shares are owned by insiders. Comparatively, 7.8% of Third Harmonic Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts prefer ORIC or THRD? Oric Pharmaceuticals currently has a consensus price target of $17.63, suggesting a potential upside of 72.29%. Third Harmonic Bio has a consensus price target of $5.00, suggesting a potential downside of 7.06%. Given Oric Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Oric Pharmaceuticals is more favorable than Third Harmonic Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oric Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90Third Harmonic Bio 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has better earnings and valuation, ORIC or THRD? Third Harmonic Bio is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOric PharmaceuticalsN/AN/A-$127.85M-$1.89-5.41Third Harmonic BioN/AN/A-$45.47M-$0.62-8.68 Does the media prefer ORIC or THRD? In the previous week, Oric Pharmaceuticals had 5 more articles in the media than Third Harmonic Bio. MarketBeat recorded 5 mentions for Oric Pharmaceuticals and 0 mentions for Third Harmonic Bio. Oric Pharmaceuticals' average media sentiment score of 0.69 beat Third Harmonic Bio's score of 0.00 indicating that Oric Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Oric Pharmaceuticals Positive Third Harmonic Bio Neutral SummaryThird Harmonic Bio beats Oric Pharmaceuticals on 7 of the 13 factors compared between the two stocks. Get Third Harmonic Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for THRD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding THRD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart THRD vs. The Competition Export to ExcelMetricThird Harmonic BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$242.80M$3.06B$5.67B$9.84BDividend YieldN/A2.28%3.93%4.04%P/E Ratio-4.3720.9283.1926.61Price / SalesN/A200.54451.26176.46Price / CashN/A44.0537.7059.65Price / Book0.858.0710.556.59Net Income-$45.47M-$53.98M$3.27B$266.12M Third Harmonic Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)THRDThird Harmonic BioN/A$5.38flat$5.00-7.1%N/A$242.80MN/A-4.37N/AORICOric Pharmaceuticals4.7378 of 5 stars$9.85+2.4%$17.63+78.9%+0.3%$934.32MN/A-5.2180IOVAIovance Biotherapeutics4.5466 of 5 stars$2.45-3.2%$11.90+385.7%-80.4%$915.49M$164.07M-1.99500GERNGeron3.0574 of 5 stars$1.46+2.8%$4.19+186.8%-69.3%$905.98M$76.99M-11.23229Positive NewsUPBUpstream Bio2.5564 of 5 stars$17.30+3.4%$56.50+226.6%N/A$901.90M$2.72M0.0038News CoveragePositive NewsTRVITrevi Therapeutics2.8032 of 5 stars$7.42+1.9%$20.11+171.0%+149.5%$886.54MN/A-17.6720News CoverageIMNMImmunome1.5616 of 5 stars$10.16+2.4%$22.50+121.5%-37.6%$863.49M$9.04M-3.3040News CoverageURGNUrogen Pharma4.5518 of 5 stars$19.50+5.4%$32.00+64.1%+38.9%$855.89M$90.40M-5.87200Positive NewsQUREuniQure2.3625 of 5 stars$15.79+1.5%$37.45+137.2%+162.5%$853.18M$27.12M-4.03500Analyst ForecastNEONeoGenomics3.2524 of 5 stars$6.70+3.9%$12.75+90.3%-46.5%$833.20M$660.57M-8.272,200News CoverageAnalyst ForecastGap UpPHATPhathom Pharmaceuticals2.5811 of 5 stars$12.58+8.7%$17.50+39.1%-25.3%$820.82M$55.25M-2.66110 Related Companies and Tools Related Companies Oric Pharmaceuticals Competitors Iovance Biotherapeutics Competitors Geron Competitors Upstream Bio Competitors Trevi Therapeutics Competitors Immunome Competitors Urogen Pharma Competitors uniQure Competitors NeoGenomics Competitors Phathom Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:THRD) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredMy NEXT $1 Trillion PredictionJames Altucher is making his next trillion-dollar prediction — and this time, it’s not Apple. He believes Elon...Paradigm Press | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Third Harmonic Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Third Harmonic Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
